Dren Bio researches and develops protein-based therapies in the treatment of cancer, autoimmune and other diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/16/2022 | Series B | $62.5MM | $xx.xx | $28.57B | Hbm Healthcare Investments | |
Price per Share
$xx.xx
Shares Outstanding
18,382,353
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Hbm Healthcare Investments
|
||||||
10/16/2020 | Series A | $60MM | $xx.xx | $9.11B | 8vc, Alexandria Venture Investments, Bvf Partners, Hbm Healthcare Investments, Mission Biocapital, Sr One, Taiho Ventures | |
Price per Share
$xx.xx
Shares Outstanding
36,054,433
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexandria Venture Investments, Bvf Partners, Hbm Healthcare Investments, Mission Biocapital, Sr One, Taiho Ventures
|
||||||
07/12/2019 | Series Seed | $6.07MM | $xx.xx | $1.52B | 8vc, Mission Biocapital | |
Price per Share
$xx.xx
Shares Outstanding
5,007,410
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Mission Biocapital
|